Αρχική World News A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients... World News A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC Από Ogkologos - 11 Αυγούστου, 2025 638 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR “If there is an under-representation of ethnic minority communities, there will... 18 Σεπτεμβρίου, 2020 Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... 7 Ιανουαρίου, 2020 Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... 24 Οκτωβρίου, 2022 Taking Time for the Everyday Things in 2024 29 Δεκεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib 2020 Cancer Incidence and Mortality in EU-27 Countries ΙΣΤΟΡΙΑ Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and...
